Latest Us Army News

Page 2 of 2
Pointerra Limited reported strong FY25 Q4 results marked by new enterprise customers, a major US defense subcontract, and significant cashflow improvements. The company’s AI-enhanced digital twin platform is gaining traction across multiple sectors, setting the stage for growth in FY26.
Sophie Babbage
Sophie Babbage
31 July 2025
Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.
Ada Torres
Ada Torres
24 July 2025
Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.
Maxwell Dee
Maxwell Dee
16 July 2025
Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.
Ada Torres
Ada Torres
12 June 2025
Pointerra Limited has joined forces with Leidos as a subcontractor on the US Army’s $499 million GRIDS IV program, aiming to enhance real-time geospatial intelligence through advanced AI and machine learning technologies.
Maxwell Dee
Maxwell Dee
8 May 2025
Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.
Ada Torres
Ada Torres
29 Apr 2025
Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.
Victor Sage
Victor Sage
6 Feb 2025
Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.
Ada Torres
Ada Torres
6 Feb 2025
Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.
Victor Sage
Victor Sage
31 Jan 2025